Unrestricted and Restricted Access to Sugammadex and Side Effect Profile in a Teaching Hospital Centre for Year 2014- Database Audit Study

Background Sugammadex is used for the rapid reversal of neuro muscular block. It was used on an unrestricted basis in our facility prior to July 2014 but has subsequently been restricted due to the removal of cost subsidies. Our aim is to determine the impact of restricting the use of Sugammadex on clinical outcomes. Methods A retrospective audit was conducted for the period January 1st to December 31st 2014. Sugammadex use was unrestricted during the first 6 months of this period and restricted over the following period. Patients who had endotracheal intubation for any surgery were included in the audit. Non- intubated patients, patients with incomplete data and patients who were intubated and transferred to the intensive care unit were excluded. The Operating Room Information System and medical records were used to obtain information on the operating theatre time, post-anesthesia care unit time and side effects such as postoperative nausea and vomiting, oxygen-de-saturation during recovery and anaphylaxis; Sugammadex usage and cost data obtained from the hospital pharmacy. Results 1347 and 1302 patients were included for the unrestricted and restricted periods, respectively. There were no significant differences between the time periods with respect to patient characteristics (Age, ASA) or side effects (oxygen de-saturation, nausea). While mean time in theatre was similar across the time periods, mean recovery time was significantly longer during the restricted period (P < 0.0001). One case of anaphylaxis was reported during the restricted period while no cases occurred during the unrestricted period. Median Sugammadex dose was 200 mg and its usage dropped by 54% in the restricted time. The cost of sugammadex was $180 AUD and Neostigmine $1.80 AUD. Conclusions Though unrestricting Sugammadex reduced recovery time but has had minimal impact on other clinical outcomes. Neostigmine represents a cheaper alternative and its use remains standard practice in our facility.

[1]  C. Fernández-Pérez,et al.  A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade , 2015, Anaesthesia.

[2]  A. Kalansky,et al.  Hypersensitivity associated with sugammadex administration: a systematic review , 2014, Anaesthesia.

[3]  Chie Nagata,et al.  Three suspected cases of sugammadex-induced anaphylactic shock , 2014, BMC Anesthesiology.

[4]  J. Takeda,et al.  [Efficacy and safety of sugammadex (Org 25969) in reversing deep neuromuscular block induced by rocuronium or vecuronium in Japanese patients]. , 2014, Masui. The Japanese journal of anesthesiology.

[5]  T. Ledowski,et al.  Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: Sugammadex, neostigmine or no reversal , 2014, European journal of anaesthesiology.

[6]  J-G Song,et al.  Investigation on acute kidney injury following colorectal surgery: predictors, impact on the postoperative outcome, and comparison of predictability in outcome between AKN and RIFLE criteria: 1AP2-8 , 2014 .

[7]  B. Baldo,et al.  Sugammadex and anaphylaxis in the operating theater. , 2014, Revista espanola de anestesiologia y reanimacion.

[8]  N. Nanjappa,et al.  Sugammadex Hypersensitivity—A Case of Anaphylaxis , 2014, Anaesthesia and intensive care.

[9]  P. Hopkins,et al.  Anaphylaxis to Sugammadex , 2014, Anaesthesia and intensive care.

[10]  Makoto Tanaka,et al.  Anaphylaxis after sugammadex administration , 2013, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[11]  M. Ozaki,et al.  1145: BE CAREFUL ABOUT ANAPHYLACTIC SHOCK BY ANTAGONISM OF THE NEUROMUSCULAR BLOCKADE ~CASES OF ANAPHYLACTIC SHOCK INDUCED BY SUGAMMADEX , 2012 .

[12]  A. Matsunaga,et al.  Three cases of suspected sugammadex-induced hypersensitivity reactions. , 2012, British journal of anaesthesia.

[13]  Y. Motoyama,et al.  [Case of anaphylactic reaction caused by sugammadex]. , 2012, Masui. The Japanese journal of anesthesiology.

[14]  R. Watts,et al.  The Influence of Unrestricted Use of Sugammadex on Clinical Anaesthetic Practice in a Tertiary Teaching Hospital , 2012, Anaesthesia and intensive care.

[15]  F. Chung,et al.  Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. , 2009, The Cochrane database of systematic reviews.

[16]  J. Stensballe,et al.  Reversal of Rocuronium-induced Neuromuscular Block by the Selective Relaxant Binding Agent Sugammadex: A Dose-finding and Safety Study , 2006, Anesthesiology.